Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Analysts expect: Zepbound: $18B in sales next year Wegovy: $16.5B Total market: $150B by 2030 And Lilly isnt stopping its next-gen oral GLP-1 (orforglipron) could widen the gap even further
Comparative GLP-1 agonist pharmacology
Most patients notice initial improvements within 2-4 weeks of starting peptide therapy, with significant changes typically occurring by 6-8 weeks
Considerations Slower onset: Because the peptide must traverse the nasal membranes and then enter general circulation (and eventually reach brain/central nervous system targets), the onset tends to be more gradual
US$ 23.18
US$ 20.68
US$ 20.32
US$ 21.81
